Read More
Investigational CAR-T therapy for Hodgkin lymphoma receives fast-track designation from FDA
Based on proof-of-concept results from clinical trials at University of North Carolina Lineberger Comprehensive Cancer Center and Baylor College of Medicine, an investigational cellular immunotherapy for Hodgkin lymphoma has received a Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration.
Read More
>>Hollywood's Exotic Secret For Healthy Weight Loss
Read More
Subscribe to:
Post Comments (Atom)
0 Response to "Investigational CAR-T therapy for Hodgkin lymphoma receives fast-track designation from FDA"
Post a Comment